Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN, 47907, USA; Center for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA.
Department of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN, 47907, USA; Center for Drug Discovery, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, USA; Purdue Institute of Inflammation, Immunology, and Infectious Disease, West Lafayette, IN, 47906, USA.
Eur J Med Chem. 2022 Oct 5;240:114550. doi: 10.1016/j.ejmech.2022.114550. Epub 2022 Jun 23.
The National Institute of Health (NIH) estimates that the majority of human microbial infections are either linked to or directly caused by bacterial biofilms and these infections are immune to most currently approved FDA drugs. Hence, there is a need for the development of potent antibiotics against biofilms. We have previously shown that pentafluorosulfanyl (SF)-containing quinoline compounds, which were synthesized via the Povarov reaction, kill persister bacteria (Onyedibe et al. RSC Med Chem, 2021, 12, 1879-1893). Inspired by this earlier discovery, we expanded upon the compounds in the library to identify additional members that could have similar or better potencies, with a goal of increasing the diversity of compounds that could be further developed into therapeutics. Compounds from the Povarov derived SF-containing compounds inhibited both clinical and laboratory strains of Gram-positive bacteria at minimum inhibitory concentration (MIC) of 0.5 μg/mL to 2 μg/mL. Interestingly, the lead compound, HSD 1919 exhibited rapid bactericidal mode of action against multidrug resistant (MDR) staphylococcal and enterococcal strains such as MRSA and VRE via bacterial membrane disruption. HSD 1919 eradicated persister MRSA in 2 h-8 h. Most remarkably, we found that HSD 1919 (newly identified compound) and HSD 1835 (previously disclosed, Onyedibe et al. RSC Med Chem, 2021, 12, 1879-1893), dispersed preformed MRSA and VRE biofilms at relatively low concentrations (8 μg/mL). Bithionol (at 1 μg/mL) or nitroxoline (at 4 μg/mL) did not appreciably disperse pre-existing biofilms but when combined with HSD 1919 or HSD 1835 (at 0.5-4 μg/mL), preformed MRSA biofilms could be dispersed, highlighting exciting synergy at reasonably low concentrations of the drugs. Biofilm dispersal was verified by scanning electron microscopy (SEM) whilst membrane disruption properties of HSD 1919 were confirmed by both transmission electron microscopy (TEM) and SEM. Further mechanistic studies showed inhibition of DNA, RNA, cell wall and protein synthesis in a macromolecular biosynthesis assay indicating that these compounds inhibit bacteria via multiple mechanisms, which is now being appreciated as an effective way to tackle resistant bacteria. Toxicity studies showed that HSD 1919 was nontoxic in-vitro to mammalian red blood cells at 10X MIC. Herein, we report HSD 1919 and analogs thereof as critical chemical scaffolds, which can be harnessed to develop highly potent antibiofilm therapeutics.
美国国立卫生研究院(NIH)估计,大多数人类微生物感染要么与细菌生物膜有关,要么直接由其引起,而这些感染对大多数目前批准的 FDA 药物具有抗药性。因此,需要开发针对生物膜的有效抗生素。我们之前已经证明,通过 Povarov 反应合成的含五氟硫基(SF)喹啉化合物可以杀死持久性细菌(Onyedibe 等人,RSC Med Chem,2021,12,1879-1893)。受这一早期发现的启发,我们在文库中对化合物进行了扩展,以确定其他可能具有相似或更好活性的成员,目标是增加可以进一步开发成治疗剂的化合物的多样性。源自 Povarov 的 SF 化合物抑制了临床和实验室来源的革兰氏阳性菌,最低抑菌浓度(MIC)为 0.5μg/mL 至 2μg/mL。有趣的是,先导化合物 HSD 1919 通过破坏细菌膜,对耐多药(MDR)葡萄球菌和肠球菌株(如 MRSA 和 VRE)表现出快速杀菌作用。HSD 1919 在 2 小时至 8 小时内消除了持久性 MRSA。最显著的是,我们发现 HSD 1919(新鉴定的化合物)和 HSD 1835(以前披露的,Onyedibe 等人,RSC Med Chem,2021,12,1879-1893)可以在相对较低的浓度(8μg/mL)下分散已形成的 MRSA 和 VRE 生物膜。双硫仑(1μg/mL)或硝呋太尔(4μg/mL)不能显著分散已存在的生物膜,但当与 HSD 1919 或 HSD 1835(0.5-4μg/mL)结合使用时,可以分散已形成的 MRSA 生物膜,突出了这些药物在合理低浓度下的协同作用。扫描电子显微镜(SEM)验证了生物膜的分散,而 HSD 1919 的膜破坏特性则通过透射电子显微镜(TEM)和 SEM 得到了证实。进一步的机制研究表明,在大分子生物合成测定中,这些化合物抑制了 DNA、RNA、细胞壁和蛋白质的合成,表明这些化合物通过多种机制抑制细菌,这现在被认为是一种有效应对耐药细菌的方法。毒性研究表明,HSD 1919 在 10X MIC 时对哺乳动物红细胞在体外没有毒性。在此,我们报告 HSD 1919 及其类似物作为关键的化学支架,可以利用它们来开发高效的抗生物膜治疗剂。